Mr. Edick is currently Chairman and Chief Executive Officer of Xeris Pharmaceuticals, a private technology-based company with an initial focus on therapies for diabetes-associated hypoglycemia. Prior to Xeris Pharmaceuticals, Mr. Edick was Founding Partner of 3G Advisors, a consultancy to the pharmaceutical, healthcare and healthcare investor communities. From 2010 to 2014, Mr. Edick was the Chief Executive Officer of Durata Therapeutics (Nasdaq: DRTX), a biopharmaceutical company addressing the growing need for new antibiotics to treat infectious diseases. Durata was acquired by Actavis plc in November 2014. Prior to Durata, Mr. Edick was Chief Executive Officer of Ganic Pharmaceuticals, a Warburg Pincus investment search vehicle, from 2008 to 2010. Before Ganic, Mr. Edick was Chief Executive Officer of MedPointe Healthcare, Inc., a US-based specialty pharmaceutical company, a position he assumed in 2006, having been President of Pharmaceutical Operations since 2002. Mr. Edick led the growth of the business and the development of a clinical stage portfolio, and the Company was subsequently sold to Meda, AB of Sweden in 2007.
Mr. Edick also has extensive industry experience with leading consumer, pharmaceutical and healthcare organizations including Pharmacia - Group Vice President and President, Asia Pacific & Latin America Operations at Pharmacia; and Searle Pharmaceuticals - President of Asia Pacific, Canada & Latin America Operations, VP, Canada & Latin America Operations, and leading the US managed care organization, US marketing organization and Global Pain & Inflammation Business, including the commercialization and launch planning for Celebrex®. In addition, Mr. Edick has also held sales, marketing, advertising and advisory positions in Procter & Gamble, Ortho Pharmaceuticals and The Hamilton Group.
Mr. Edick currently serves as the Chairman of the Board of Iterum Therapeutics. Mr. Edick has also previously served on a number of pharmaceutical and healthcare company boards, including PDL BioPharma (Nasdaq: PDLI), Neos Therapeutics (Nasdaq: NEOS), NewLink Genetics Inc. (Nasdaq: NLNK), Circassia Pharmaceuticals plc (London: CIR.L), Sucampo Pharmaceuticals, (acquired by Mallinckrodt), Amerita Inc., and Informed Medical Communications. He was also Chairman of the Board of Life Cycle Pharma Ltd (fka Veloxis).
Mr. Edick holds a Bachelor of Arts in Psychology from Hamilton College.
What is Paul R. Edick's net worth?
The estimated net worth of Paul R. Edick is at least $6.93 million as of August 9th, 2023. Mr. Edick owns 2,288,064 shares of Xeris Biopharma stock worth more than $6,932,834 as of November 21st. This net worth evaluation does not reflect any other assets that Mr. Edick may own. Additionally, Mr. Edick receives an annual salary of $1,210,000.00 as Insider at Xeris Biopharma. Learn More about Paul R. Edick's net worth.
How old is Paul R. Edick?
What is Paul R. Edick's salary?
How do I contact Paul R. Edick?
Has Paul R. Edick been buying or selling shares of Xeris Biopharma?
Paul R. Edick has not been actively trading shares of Xeris Biopharma over the course of the past ninety days. Most recently, on Wednesday, August 9th, Paul R. Edick bought 10,000 shares of Xeris Biopharma stock. The stock was acquired at an average cost of $2.38 per share, with a total value of $23,800.00. Following the completion of the transaction, the insider now directly owns 2,288,064 shares of the company's stock, valued at $5,445,592.32. Learn More on Paul R. Edick's trading history.
Are insiders buying or selling shares of Xeris Biopharma?
In the last year, Xeris Biopharma insiders bought shares 3 times. They purchased a total of 14,185 shares worth more than $29,973.45. The most recent insider tranaction occured on August, 9th when Director John P Schmid bought 4,285 shares worth more than $10,155.45. Insiders at Xeris Biopharma own 4.6% of the company.
Learn More about insider trades at Xeris Biopharma. Information on this page was last updated on 8/9/2024.
